Mambisa is a formulation with two proteins, which are two antigens obtained through recombinant DNA techniques. Protein subunit vaccines are very safe. They are very innocuous formulations and do not have any possibility of causing infection, since they are part of the most important protein of the virus, obtained by means of recombinant DNA techniques, purified to high levels of purity. In addition, they are technologies that allow them to be combined with each other and with other more complex technologies.
Mambisa combines two antigens: that of the nucleocapsid of the hepatitis B virus, extensively studied at the CIGB, which has the ability to stimulate the immune response at the mucosal level and in the systemic compartment, bound to the RBD antigen which is Abdala . It is applied intranasally.
This route of administration was chosen because the virus penetrates mainly through the nostrils, and in these compartments there is an immune system. In the mucosa, immunoglobulins of the IgA type are generally activated. When it comes to measuring antibodies, we almost always talk about IgG immunoglobulins, which are of the systemic class and are stimulated when vaccinated intramuscularly. The immunological memory in this case is of cells that, when faced with a new antigen, will awaken IgG type antibodies.
If you are vaccinated intranasally, there will be another type of immunoglobulins, which are IgA, and even IgA are present in the mucosa, forming a dimer, which expresses a higher inhibition and neutralization capacity. Systemically they are also present, but in monomeric form. Intranasal vaccination is thought to provide a barrier to infection, prevent virus replication, and decrease viral shedding.
